Ola Magne Vagnildhaug, Trude R Balstad, Inger Ottestad, Asta Bye, Christine Greil, Jann Arends, Vickie Baracos, Leo R Brown, Olav F Dajani, Ross D Dolan, Marie Fallon, Eilidh Fraser, Aleksandra Grzyb, Marianne J Hjermstad, Gunnhild Jakobsen, Stein Kaasa, James McDonald, Iain Philips, Judith Sayers, Melanie R Simpson, Mariana S Sousa, Richard J E Skipworth, Barry J A Laird, Tora S Solheim
There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and evaluate endpoints used to assess appetite and dietary intake in cancer cachexia clinical trials. A search for studies published from 1 January 1990 until 2 June 2021 was conducted using MEDLINE, Embase and Cochrane Central Register of Controlled Trials. Eligible studies examined cancer cachexia treatment versus a comparator in adults with assessments of appetite and/or dietary intake as study endpoints, a sample size ≥40 and an intervention lasting ≥14 days...
February 11, 2024: Journal of Cachexia, Sarcopenia and Muscle